Development and validation of nonalcoholic fatty liver disease test: a simple sensitive and specific marker for early diagnosis of nonalcoholic fatty liver disease

Simple item page
dc.contributor.authorOmran, Mohamed
dc.contributor.authorOmr, Mona
dc.contributor.authorMohamed, Amal A.
dc.contributor.authorAbdelghafour, Reem A.
dc.contributor.authorMuharram, Nashwa M.
dc.contributor.authorHassan, Mohamed B.
dc.contributor.authorFangry, Abobakrelsedik
dc.contributor.authorEmran, Tarek
dc.contributor.authorArab, Juan P.
dc.contributor.authorArnold, Jorge
dc.contributor.authorDiaz, Luis Antonio
dc.contributor.authorZheng, Ming-Hua
dc.contributor.authorEl-Kassas, Mohamed
dc.date.accessioned2025-01-20T20:09:01Z
dc.date.available2025-01-20T20:09:01Z
dc.date.issued2023
dc.description.abstractAimThis study aimed to develop a noninvasive test for identifying patients with nonalcoholic fatty liver disease (NAFLD) based on clinical and routine laboratory data. MethodsThe developed model 'NAFLD test' was compared to the most commonly used NAFLD scores and then validated in three groups of NAFLD patients from five centers in Egypt, China, and Chile. Patients were divided into the discovery cohort (n = 212) and the validation study (n = 859). The ROC curve and stepwise multivariate discriminant analysis were used to develop and validate the NAFLD test and evaluate its diagnostic performance, which was then compared to other NAFLD scores. ResultsElevated C-reactive protein (CRP), cholesterol, BMI, and alanine aminotransferase (ALT) levels were significantly associated with NAFLD (P < 0.0001). NAFLD test is depicted as (-0.695 + 0.031 x BMI + 0.003 x cholesterol + 0.014 x ALT + 0.025 x CRP) to discriminate patients with NAFLD from healthy individuals. The area under the ROC curve (AUC) of the NAFLD test was 0.92 [95% confidence interval (CI): 0.88-0.96]. The NAFLD test was the most accurate diagnostic indicator of NAFLD when compared to widely used NAFLD indices. Upon validating the NAFLD test, its AUC (95% CI) for distinguishing patients with NAFLD from healthy individuals was 0.95 (0.94-0.97), 0.90 (0.87-0.93), and 0.94 (0.91-0.97) in Egyptian, Chinese, and Chilean patients with NAFLD respectively. ConclusionThe NAFLD test is a new validated diagnostic biomarker that can be utilized for the early diagnosis of NAFLD with high diagnostic performance.
dc.fuente.origenWOS
dc.identifier.doi10.1097/MEG.0000000000002575
dc.identifier.eissn1473-5687
dc.identifier.issn0954-691X
dc.identifier.urihttps://doi.org/10.1097/MEG.0000000000002575
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91959
dc.identifier.wosidWOS:001022267500011
dc.issue.numero8
dc.language.isoen
dc.pagina.final880
dc.pagina.inicio874
dc.revistaEuropean journal of gastroenterology & hepatology
dc.rightsacceso restringido
dc.subjectdiagnostic
dc.subjectmarker
dc.subjectnonalcoholic fatty liver disease
dc.subjectnoninvasive
dc.subjectscore
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleDevelopment and validation of nonalcoholic fatty liver disease test: a simple sensitive and specific marker for early diagnosis of nonalcoholic fatty liver disease
dc.typeartículo
dc.volumen35
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas